Panel Discussion: From AI Adoption to AI Accountability – What Has AI Actually Delivered for GPCR Discovery?

11:00 am - Tuesday 2nd March 2027

  • Where has AI demonstrably delivered measurable impact on GPCR hit identification, optimization and candidate selection?
  • What benchmarks and validation frameworks do the field need to credibly assess AI platform performance against traditional methods?
  • As AI capabilities expand, where does biological expertise and experimental validation remain non negotiable in the decision-making process?

Speakers:

Co-Founder
alphamol
Head of Biology & Translational Sciences
Abundance Biopharma
Chief Technology Officer & Co-Founder
LEMBAS
Director - Strategic Drug Discovery Initiatives
Recursion